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Abstract  
 
Provision and participation in formal external continuing medical education (CME) is 
costly. Employer or state support of CME is the exception rather than the rule. The 
medical industry has supported both providers and consumers of educational activities, 
leading to concerns of commercial bias. Recent medical industry initiatives in Europe to 
improve the transparency of the relationship between industry and the profession, 
including the field of medical education, have had the paradoxical effect of the industry 
playing an increasingly direct role in the provision of physician education. Funding of 
medical professional society annual congresses has been directly and indirectly 
jeopardised. Acknowledging that there are areas of co-operation in the field of education 
between the medical profession and the medical industry from which both can benefit, we 
argue that medical education requires an objective approach that the primary fiduciary 
duty of medical industry companies precludes. Medical professional societies, as not-for-
profit organisations whose core mission is the development and promotion of best 
practice, are best placed to guide and deliver medical education to their members. 
 
 
Key words 
Continuing medical education, healthcare industry, medical professional societies, 
financial support, conflict of interest 
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Introduction 
 
Everyone in society has an interest in physicians and other healthcare professionals 
performing well – training doctors is costly and often subsidized by public funds, 
healthcare consumes a large portion of national finances, and at some time or other, most 
members of society will become a patient. The pace of scientific progress places a 
particular onus on medical professionals to adapt continuously to novel and better 
approaches to manage their patients. Best practice guidelines are helpful but there are 
important gaps between these recommendations and what is delivered in clinical practice. 
Maintaining knowledge and skills requires continuous and unbiased medical education for 
physicians and other health care professionals, and continuing medical education (CME) 
has become an essential component of efforts to ensure high quality practice. 
 
The greater part of a doctor’s development as a physician occurs after qualification; but in 
contrast to the well-defined and regulated process of undergraduate medical training and 
the ensuing specialist training, CME is variable in form and scale in Europe and around 
the world (1). Increasingly, state licencing systems have adopted models of formal 
continuing professional development (CPD) of which CME is a key part. Regulation varies 
from no monitoring system of CPD, to an honour-based commitment to engage in a pre-
specified minimum amount of CME, to registration of a range of CPD activities, to formal 
examination and periodic re-certification. National and international CME accreditation 
authorities have drawn up criteria to ensure high quality CME (2, 3, 4, 5). In an effort to 
avoid commercial bias in events and programmes that receive financial support from the 
industry, the European Accreditation Council for Continuing Medical Education (EACCME) 
requires that ‘all funding from sponsors must be provided as an unrestricted educational 
grant, free of any attempt to influence the programme, individual sessions, subjects for 
discussion, content or choice of faculty members’ (2).  
 
The medical industry has played a prominent supportive role in medical education in 
recent decades. This support raised ethical concerns related to both industry and 
healthcare providers. Much has been done to ensure a balanced and unbiased 
presentation of data, and a robust separation of educational and marketing interests. 
However, there are indications that the industry intends to play a more direct role in 
educating healthcare professionals, and in the process, to withdraw or reduce unrestricted 
financial support of medical professional organisations with whom they have previously 
partnered. This paper puts forward the position of the Biomedical Alliance in Europe (the 
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BioMed Alliance), an umbrella organisation representing the views of twenty seven 
medical organisations and more than 400,000 healthcare professionals and researchers 
in Europe. We describe the current roles and responsibilities of the medical professional 
societies and the medical industry in medical education and the development of the 
Industry adopting a more direct role in CME. We argue in favour of measures that 
guarantee an ethical and transparent relationship between medical professional societies 
and the medical industry in the field of medical education that promote the best outcomes 
for patients through unbiased, high quality CME. 
 
 
Role of Professional Medical Societies 
 
Doctors seek knowledge in a wide variety of ways. Medical journals, medical websites or 
other digital resources (social networks,  dedicated blogs) and, to a lesser extent, 
textbooks are used for self-learning. Learning in practice, small group educational 
meetings, multidisciplinary discussions (both formal and informal) and interactive 
workshops in particular have been shown to be effective (6,7). Large meetings including 
national and international symposia and specialty congresses remain the most popular 
form of external CME for European physicians (8). In this context, medical professional 
societies play a central role in the provision of CME, based on best available evidence, at 
national and international level. Their digital learning portfolios are available for continuous 
self-directed and blended learning. Their congresses are designed to educate 
professionals by highlighting the key messages of international or national clinical practice 
guidelines and their application in daily clinical work, the outcomes of the latest research, 
and increasingly by way of dedicated educational programmes integrated into medical 
congresses. They offer a unique opportunity for face to face educational engagement with 
their peers and with experts. Best practice frequently requires an understanding of areas 
of practice devoid of commercial interest, not least avoiding unnecessary investigations or 
treatments, and requires an independent and balanced educational perspective. The not-
for-profit nature of medical professional societies, their constitution, systems of 
governance and essentially altruistic goals make them particularly suited to designing and 
delivering unbiased medical education.  
 
 
Role of Medical Industry 
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The medical industry plays a key role in the development of novel technologies, devices 
and medications, in close collaboration with clinical scientists and physicians. There is a 
regulatory requirement for the industry to ensure safe use of its pharmaceutical products 
(9) and devices (10). These requirements mandate a certain level of training in the safe 
and effective use of products. Procedural training in the use of complex devices is 
frequently device specific and focused on correct application and handling. Product 
training has different goals and requirements than medical education which provides an 
unbiased overview of available approaches. Through the process of research and 
development of new pharmacological and technical approaches to disease, the industry 
has built up a deep and wide knowledge base of educational value. The most widely 
applied, and generally accepted, model of industry involvement in medical education is 
provision of unrestricted educational grants to CME providers, on the express 
understanding that all reasonable measures are taken to avoid biased educational 
messages. Less clearly unbiased educational meetings or online programmes that offer 
an opportunity to showcase products are funded and designed by industry through 
intermediary Medical Education and Communication Companies (MECCs). The industry 
plays an even more direct role in medical education and training through training 
institutes, educational foundations, ‘Excellence Programmes’, and, in some parts of the 
world, is the sole provider of CME. The larger industry companies have workforces 
numbering into the tens of thousands, and have developed sophisticated educational 
programmes for their employees, expertise some companies are keen to utilise to educate 
doctors (11,12).  
 
 
Greater Industry Engagement in Education and its Impact 
 
Some commentators view any industry involvement in medical education of physicians as 
unacceptable (13), while others take a more nuanced and pragmatic view (14, 15). 
Concerns relating to the introduction of bias in physician education and wider concerns 
regarding the interaction of industry and medical professionals has led to regulation. This 
includes the Sunshine Act in the United States and ‘soft legislation’ produced by the 
European Commission in 2012 when the ‘List of Guiding Principles Promoting Good 
Governance in the Pharmaceutical Sector’ was published by the Platform on Ethics & 
Transparency (16). Soon after, the representative organisation for the pharmaceutical 
industry in Europe, EFPIA (The European Federation of Pharmaceutical Industries and 
Associations), and its medical device equivalent, MedTech Europe, produced guiding 
Codes of Conduct for their members (17,18) outlining appropriate interaction with 
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physicians, including the nature and support for educational meetings. Our organisation, 
the BioMed Alliance, produced a Code of Conduct outlining the ethical basis for the 
interaction of medical professionals and industry (19) (Table 1). 
 
The MedTech code prohibits direct sponsorship of individual healthcare professionals to 
attend meetings organised by Professional Medical Societies, but allows support of third 
parties to organise meetings, including medical professional societies and MECCs. The 
EFPIA code (17) allows support for physicians to attend third party meetings, details of 
which are published (with the individual’s agreement) on an open access national register 
on the national pharmaceutical organisation’s website. 
 
Whereas the anticipated effect of the industry codes was to promote a more transparent 
and ethically sound interaction between industry and medical professionals, the actual 
outcome, at least in the field of education, has been contradictory. Some industry 
companies increasingly adopt a direct role in designing “educational programmes” on their 
own, without adequate governance to protect such programmes against bias relating to 
their own products (10). 
 
The industry’s fiduciary duty is to its shareholders and owners, a position that introduces 
inevitable bias in matters relating to information about its products. The narrow focus of 
drug or device specific training often lack context, and is less likely to promote a balanced 
approach to patient management. The converse is also true – patent-free and non-
pharmacological treatment, and management strategies that have no inherent commercial 
value, including those that reveal waste or redundancy in current therapeutic approaches, 
are unlikely to be of interest from an industry perspective, but can be central to promotion 
of high value patient care.   
 
The ubiquity of bias is put forward as a reason as to why the industry should not be 
excluded from a more active engagement in medical education (11). Like other stake 
holders, clinicians, academics, scientists and the organisations to whom they belong 
certainly have conflicts of interest that can introduce bias into educational programmes. 
Be they scientific, financial, professional or otherwise, governance systems set out to 
manage conflict of interest by recognition, declaration and, when it is judged likely they will 
introduce harmful bias, recusal or exclusion from the relevant activity. Importantly, the 
fiduciary duty of physicians is towards their patients, not towards shareholders. An 
argument of moral equivalence of educational bias faced by industry and medical 
professional societies is misleading. 
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Proposals for the Future of Continuing Medical Education 
 
Development and delivery of CME by medical professional societies is an expensive 
undertaking. It is made possible by the input of volunteer professional members as 
developers, guideline writers, organisers, and faculty; by membership fees; and, to a 
significant degree, industry financial support. A small proportion of the funding of CME 
comes from statutory bodies, tax relief or healthcare and academic institutions. Recent 
developments of diminishing financial sponsorship and a growing move to greater direct 
involvement of the Industry threatens the role and viability of medical professional 
societies in provision of balanced, high quality medical education. It can be anticipated the 
consequences will be felt unequally; physicians in low and middle income countries 
affected to a greater extent. Civil society is served by medical professional societies in 
their role fostering and generating independent science, education and training. 
Policymakers should be aware that measures that erode these activities risk negative 
consequences for unbiased patient centred clinical decision making and patient safety. 
 
Medical professional societies are best placed to provide independent, unbiased and 
effective CME. Accreditation authorities have recently reiterated the requirements for high 
quality CME that must be followed for educational events and programmes to be 
accredited and for which CME credits may be granted (20).  The concerns of external 
observers, of healthcare professionals and industry relating to inappropriate interactions 
have led to Codes of Conduct that were meant to pave the way towards a mutually 
respectful, transparent and ethical relationship between the profession and the industry. A 
frank discussion between the profession, the industry, payors, the public, and regulators is 
needed to determine the best environment for unbiased CME. Health care providers and 
payors, including state and private hospital owners and health insurers, also have a role to 
play in the funding of CME. The industry has constructively highlighted the importance of 
contemporary, needs based, outcome oriented, educational approaches (11). For its part, 
the medical profession should commit to these principles and ongoing innovation in 
medical education. Although the industry has an overriding commercial responsibility to its 
shareholders, it also has an ethical responsibility to see its products used safely, 
effectively and appropriately for the benefit of patients and society. We argue this is better 
achieved by support of medical professional societies in their role as educators, rather 
than itself taking on those activities.  
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Clinical significance 
 
This will be submitted off-line as discussed with the editor in chief. Dr Alpert. 
 Maintaining knowledge and skills requires continuous and unbiased medical 
education  
 
 Accreditation systems have been devised to avoid bias in cases of industry support 
of continuing medical education (CME) 
 
 Medical professional societies are central to provision of unbiased CME at 
international level 
 
 The collaboration between the medical professional societies and the medical 
industry in the field of education involves inevitable challenges as well as important 
opportunities 
 
 The future lies in agreeing roles and responsibilities and a controlled and 
transparent cooperation between the medical profession and industry 
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Table 1 
Key legislation and non-governmental organisation codes of conduct relating to ethics 
and transparency in the relationship between health professionals and medical industry 
 
 Sunshine Act, part of Patient Protection and Affordable Care Act, enacted in the 
United States 2010 
 
 ‘List of Guiding Principles Promoting Good Governance in the Pharmaceutical 
Sector’ published by the European Union Platform on Ethics & Transparency (16) 
2012 
 
 Biomedical Alliance in Europe Code of Conduct (19) published 2016  
 
 European Federation of Pharmaceutical Industries and Associations (EFPIA) 
Disclosure Code (17) activated mid 2016  
 
 MedTech Europe Code of Ethics Business Practice (18) became binding for its 
Corporate Members from the start of 2017  
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